Aldeyra Therapeutics Inc

aldeyra.com

Aldeyra Therapeutics (NASDAQ: ALDX) is a clinical-stage biopharmaceutical company focused on developing therapies for immune-mediated and metabolic diseases. The filing excerpts provided do not contain sufficient detail to describe its revenue model, product pipeline, competitive position, geographic footprint, leadership, or financial structure. Based solely on the available filing content, no further factual claims can be supported.

Peers: ALPINE IMMUNE SCIENCES, INC. MiMedx Group Inc Atara Biotherapeutics Inc Biomea Fusion Inc BioXcel Therapeutics Inc Foghorn Therapeutics Inc Omega Therapeutics, Inc. Prelude Therapeutics Inc Tyra Biosciences Inc

Source: SEC 10-K, filed 2026-02-27

Dive deeper

Financial Snapshot

Revenue

TTM

$0.00

Gross Margin

Last 4 Quarters

N/A

Net Income

TTM

-$27.37M

Current Assets

2026 Q1

$66.27M

Current Liabilities

2026 Q1

$24.33M

Current Ratio

2026 Q1

272.44%

Total Assets

2026 Q1

$66.48M

Total Liabilities

2026 Q1

$24.33M

Book Value

2026 Q1

42.16M

Cash

2026 Q1

$65.00M

P/E

Last 4 Quarters

N/A

Free Cash Flow

Last 4 Quarters

N/A

Stock Price

Market Cap: $124.86 Million